Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial

Overview of attention for article published in The Lancet, September 2017

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news: 58 news outlets
blogs: 6 blogs
policy: 1 policy source
twitter: 1174 X users
patent: 1 patent

facebook: 12 Facebook pages
reddit: 3 Redditors
guideline: 1 clinical guideline source
bluesky: 5 Bluesky users

Readers on

mendeley: 572 Mendeley

So far, Altmetric has seen 13 public wall posts from 12 users.

Tropical Medicine Graduate Program, JABSOM, University of Hawaii, 05 Dec 2017

"This study shows that many important individual clinical and global public health outcomes are prevented by 9vHPV vaccination…

Tropical Medicine Graduate Program, JABSOM, University of Hawaii, 14 Nov 2017

The 9vHPV vaccine could potentially provide broader coverage and prevent 90% of cervical cancer cases worldwide. https://www.ncbi…

Alberto Ravaioli Medicina Online, 10 Nov 2017

Il Vaccino contro l'infezione genitale da HPV , quello nonovalente, funziona e protegge per il 90% dalle infezioni HPV oncogene…

Labome News, 21 Sep 2017

A #vaccine to prevent most cervical cancers proven to be effective in a study including 14,215 women in 18 countries. https://goo…

This page shows the most recent Facebook posts that mention this research output. Click here to find out how to access more activity, including 9 additional Facebook posts.